Exelixis drives debt-free growth through Cabometyx and zanzalintinib with share buybacks and a $55 price target. Find out why EXEL stock is a strong buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback